Matrixyl
Palmitoyl Pentapeptide-4 (pal-KTTKS)
Early-stage clinical evidence exists but is limited. Larger, well-controlled trials are needed.
A cosmetic skincare ingredient that signals skin cells to produce more collagen (the protein that keeps skin firm) by mimicking a natural signal that appears when collagen breaks down. A 12-week clinical trial of 93 people showed significant wrinkle reduction compared to placebo, though most supporting research has been industry-funded.
This entry is a cited research summary, not an established treatment reference. Dosing language is included as source context, not as medical instruction.
Safety Summary
Matrixyl has a favorable safety profile with over 20 years of commercial use. The CIR assessed palmitoyl pentapeptide-4 as safe in cosmetic formulations. The EWG gives it a safety score of 1 (very safe). Robinson et al. (2005) reported good tolerability across all skin types in their 93-subject RCT. No serious adverse effects have been reported in the literature. Minor skin irritation is possible at very high concentrations, but Matrixyl is effective at extremely low concentrations (as low as 3 ppm), minimizing risk. Suitable for sensitive skin. However, systematic human safety reporting is limited -- the FDA FAERS database contains no adverse event reports for Matrixyl, which reflects absence of drug-level monitoring rather than proof of long-term safety (PMID 39858482).
Clinical check-in
If real-world use or exposure is being considered, review potential interactions, contraindications, and monitoring needs with a licensed clinician rather than relying on summary copy alone.
Sources: [1-11]